Table 1.

Clinical characteristics of the whole cohort

Clinical parameterTotalPAM50 subtype (all N = 786)
Luminal ALuminal BHER2BasalNormal
Sample sizen78637232964516
Follow-up times in recurrence-free patients (y)Median (min-max)9.7 (0.12-18)12 (0.25-18)7.6 (0.12-18)7.3 (0.47-18)2.3 (0.6-4.1)13 (3.2-18)
Follow-up-times in disease-specific surviving patients (y)Median (min-max)12 (0.55-18)13 (0.57-18)10 (0.64-18)8.8 (0.55-18)5 (1.6-16)14 (3.2-18)
Age (y)Median67676866.56568.5
PremenopausalYes20107210
No75235831462414
Unknown/pregnant1448002
SurgeryComplete mastectomy46821020339511
Partial mastectomy3061591192305
Other1237200
Axillary node dissectionYes74534931362516
No412316200
Radiation therapyYes4192071644017
No3671651652449
Tumor size (cm)Median2.12.02.52.53.52.3
T stage (clinical)T0/IS100001
T13311801182733
T23801651792826
T31895301
T4341017304
TX22810301
No. positive nodes0222959719110
1-33601821482613
4-912555531223
10+261014200
Unknown533017510
GradeGrade 1: well differentiated34255112
Grade 2: moderately differentiated3381861291409
Grade 3: poorly differentiated3701351794835
Unknown442616110
Histologic subtypeDuctal NOS70832930260413
Lobular613221413
Mucinous743000
Tubular761000
Medullary211000
Apocrine101000
Lymphovascular invasionYes4852102204429
No262139941937
Unknown392315100
Clinical ER status (DCC ligand-binding assay)Missing953001
Negative (0-9 fmol/mg)932400
Positive (>10 fmol/mg)76836432460515
Median (fmol/mg)254.5255.5327.074.032.054.0
Clinical PR status (DCC ligand-binding assay)Missing16184531527
Negative (0-9 fmol/mg)7215391800
Positive (>10 fmol/mg)5532732373139
Median (fmol/mg)12920284.517153239
IHC HER2 with FISH correction on 2+ casesNegative69634829434416
Positive7515302910
Unknown1595100

Abbreviation: NOS, not otherwise specified.